Cargando…
Effect of Cisplatin Arterial Infusion (CAI) on Primary Nonmetastatic Pelvic Osteosarcoma: A Preliminary Study
PURPOSE: The critical role of arterial infusion chemotherapy in the multimodal treatment of extremity bone cancer has been investigated extensively, but few studies have focused on pelvic osteosarcoma. Therefore, we attempted to evaluate the clinical significance of arterial infusion chemotherapy in...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894794/ https://www.ncbi.nlm.nih.gov/pubmed/33623429 http://dx.doi.org/10.2147/CMAR.S294677 |
_version_ | 1783653301228666880 |
---|---|
author | Hu, Xuantao Chen, Xia Li, Tao Liu, Zicheng Guo, Xiaoning Ouyang, Zhengxiao |
author_facet | Hu, Xuantao Chen, Xia Li, Tao Liu, Zicheng Guo, Xiaoning Ouyang, Zhengxiao |
author_sort | Hu, Xuantao |
collection | PubMed |
description | PURPOSE: The critical role of arterial infusion chemotherapy in the multimodal treatment of extremity bone cancer has been investigated extensively, but few studies have focused on pelvic osteosarcoma. Therefore, we attempted to evaluate the clinical significance of arterial infusion chemotherapy in the treatment of pelvic osteosarcoma. PATIENTS AND METHODS: We combined a cisplatin arterial infusion regimen with multidrug systematic chemotherapy as a neoadjuvant protocol for the treatment of pelvic osteosarcoma. The course number and dosage of cisplatin arterial infusion were adjusted to achieve a maximal tumor response evaluated by contrast-enhanced MRI per RECIST 1.1. Good responders received the same systematic combination for postoperative chemotherapy, and poor responders received second-line therapy. Twelve patients with nonmetastatic high-grade pelvic osteosarcoma were included. Survival, chemotherapy response and adverse events data were analyzed. RESULTS: The mean follow-up period was 56.1 months. Four patients died of refractory tumor progression, and 1 patient with local recurrence had no evidence of disease for 27 months after receiving secondary amputation and resection. Kaplan-Meier survival analysis demonstrated a 57.8% overall survival and 52.5% event-free survival rate at 5 years. Eight of 12 patients had a >90% tumor necrosis rate according to histopathologic examinations. The rates of local adverse events were lower than those reported for extremity osteosarcoma. CONCLUSION: Our study initially indicated that the cisplatin arterial infusion regimen was a potential therapy with good tolerance in the treatment of pelvic osteosarcoma. |
format | Online Article Text |
id | pubmed-7894794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-78947942021-02-22 Effect of Cisplatin Arterial Infusion (CAI) on Primary Nonmetastatic Pelvic Osteosarcoma: A Preliminary Study Hu, Xuantao Chen, Xia Li, Tao Liu, Zicheng Guo, Xiaoning Ouyang, Zhengxiao Cancer Manag Res Original Research PURPOSE: The critical role of arterial infusion chemotherapy in the multimodal treatment of extremity bone cancer has been investigated extensively, but few studies have focused on pelvic osteosarcoma. Therefore, we attempted to evaluate the clinical significance of arterial infusion chemotherapy in the treatment of pelvic osteosarcoma. PATIENTS AND METHODS: We combined a cisplatin arterial infusion regimen with multidrug systematic chemotherapy as a neoadjuvant protocol for the treatment of pelvic osteosarcoma. The course number and dosage of cisplatin arterial infusion were adjusted to achieve a maximal tumor response evaluated by contrast-enhanced MRI per RECIST 1.1. Good responders received the same systematic combination for postoperative chemotherapy, and poor responders received second-line therapy. Twelve patients with nonmetastatic high-grade pelvic osteosarcoma were included. Survival, chemotherapy response and adverse events data were analyzed. RESULTS: The mean follow-up period was 56.1 months. Four patients died of refractory tumor progression, and 1 patient with local recurrence had no evidence of disease for 27 months after receiving secondary amputation and resection. Kaplan-Meier survival analysis demonstrated a 57.8% overall survival and 52.5% event-free survival rate at 5 years. Eight of 12 patients had a >90% tumor necrosis rate according to histopathologic examinations. The rates of local adverse events were lower than those reported for extremity osteosarcoma. CONCLUSION: Our study initially indicated that the cisplatin arterial infusion regimen was a potential therapy with good tolerance in the treatment of pelvic osteosarcoma. Dove 2021-02-15 /pmc/articles/PMC7894794/ /pubmed/33623429 http://dx.doi.org/10.2147/CMAR.S294677 Text en © 2021 Hu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Hu, Xuantao Chen, Xia Li, Tao Liu, Zicheng Guo, Xiaoning Ouyang, Zhengxiao Effect of Cisplatin Arterial Infusion (CAI) on Primary Nonmetastatic Pelvic Osteosarcoma: A Preliminary Study |
title | Effect of Cisplatin Arterial Infusion (CAI) on Primary Nonmetastatic Pelvic Osteosarcoma: A Preliminary Study |
title_full | Effect of Cisplatin Arterial Infusion (CAI) on Primary Nonmetastatic Pelvic Osteosarcoma: A Preliminary Study |
title_fullStr | Effect of Cisplatin Arterial Infusion (CAI) on Primary Nonmetastatic Pelvic Osteosarcoma: A Preliminary Study |
title_full_unstemmed | Effect of Cisplatin Arterial Infusion (CAI) on Primary Nonmetastatic Pelvic Osteosarcoma: A Preliminary Study |
title_short | Effect of Cisplatin Arterial Infusion (CAI) on Primary Nonmetastatic Pelvic Osteosarcoma: A Preliminary Study |
title_sort | effect of cisplatin arterial infusion (cai) on primary nonmetastatic pelvic osteosarcoma: a preliminary study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894794/ https://www.ncbi.nlm.nih.gov/pubmed/33623429 http://dx.doi.org/10.2147/CMAR.S294677 |
work_keys_str_mv | AT huxuantao effectofcisplatinarterialinfusioncaionprimarynonmetastaticpelvicosteosarcomaapreliminarystudy AT chenxia effectofcisplatinarterialinfusioncaionprimarynonmetastaticpelvicosteosarcomaapreliminarystudy AT litao effectofcisplatinarterialinfusioncaionprimarynonmetastaticpelvicosteosarcomaapreliminarystudy AT liuzicheng effectofcisplatinarterialinfusioncaionprimarynonmetastaticpelvicosteosarcomaapreliminarystudy AT guoxiaoning effectofcisplatinarterialinfusioncaionprimarynonmetastaticpelvicosteosarcomaapreliminarystudy AT ouyangzhengxiao effectofcisplatinarterialinfusioncaionprimarynonmetastaticpelvicosteosarcomaapreliminarystudy |